Intercentre heterogeneity and determinants of implantable cardioverter-defibrillator technology selection in France.

Real-world use of abbreviated dual antiplatelet therapy after percutaneous coronary intervention among patients with high bleeding risk: Are guidelines followed? Insights from the FRANCE-PCI registry.

Beyond the aortic rim: Additional considerations in risk stratification for transcatheter atrial septal defect closure. Letter in response to the article entitled "Transcatheter closure of ostium secundum atrial septal defects in 2253children and adults: Early outcomes" by Albenque et al.

Response to "Beyond the aortic rim: Additional considerations in risk stratification for transcatheter atrial septal defect closure", a letter from Teruhiko Imamura commenting on the article entitled "Transcatheter closure of ostium secundum atrial septal defects in 2253 children and adults: Early outcomes" by Albenque et al.

Lessons learned during my collaboration with Alain Carpentier: A 25-year perspective.

Generation and study of the ANKRD1 I280V mutation in human induced pluripotent stem cells derived cardiomyocytes (hiPSC-CMs)

Intercentre heterogeneity and determinants of implantable cardioverter-defibrillator technology selection in France.

Real-world use of abbreviated dual antiplatelet therapy after percutaneous coronary intervention among patients with high bleeding risk: Are guidelines followed? Insights from the FRANCE-PCI registry.

Beyond the aortic rim: Additional considerations in risk stratification for transcatheter atrial septal defect closure. Letter in response to the article entitled "Transcatheter closure of ostium secundum atrial septal defects in 2253children and adults: Early outcomes" by Albenque et al.

Response to "Beyond the aortic rim: Additional considerations in risk stratification for transcatheter atrial septal defect closure", a letter from Teruhiko Imamura commenting on the article entitled "Transcatheter closure of ostium secundum atrial septal defects in 2253 children and adults: Early outcomes" by Albenque et al.

Lessons learned during my collaboration with Alain Carpentier: A 25-year perspective.

Generation and study of the ANKRD1 I280V mutation in human induced pluripotent stem cells derived cardiomyocytes (hiPSC-CMs)